Author:
Durand-Martel Pascali,Tremblay Dominic,Brodeur Catherine,Paquet Nancy
Abstract
Positron emission tomography (PET) imaging with F18-fluorodeoxyglucose (FDG) is increasingly used as an adjunct to clinical evaluation in the diagnosis of dementia. Considering that most FDG-PET studies in dementia use clinical diagnosis as gold standard and that clinical diagnosis is approximately 80% sensitive or accurate, we aim to review the evidence-based data on the diagnostic accuracy of brain FDG-PET in dementia when cerebral autopsy is used as gold standard. We searched the PubMed and Medline databases for dementia-related articles that correlate histopathological diagnosis at autopsy with FDG-PET imaging and found 47 articles among which there were only 5 studies of 20 patients or more. We were able to conclude that sensitivity and specificity of FDG-PET for Alzheimer's disease are good, but more studies using histopathological diagnosis at autopsy as gold standard are needed in order to evaluate what FDG-PET truly adds to premortem diagnostic accuracy in dementia.
Publisher
Cambridge University Press (CUP)
Subject
Clinical Neurology,Neurology,General Medicine
Reference70 articles.
1. Lack of correlation of regional neuropathology to the regional PET metabolic deficits in Alzheimer’s disease;Barker;J Cereb Blood Flow Metab.,1991
2. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging;Silverman;J Nucl Med.,2004
3. Positron emission tomography and histopathology in Creutzfeldt-Jakob disease
4. Comparative value of 99mTc-ECD SPECT and 18FDG PET in atypical dementia: a pilot study with longitudinal follow-up;Paquet;Eur J Nucl Med.,2008
5. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline